Natco Pharma has received seven observations from the US Food and Drug Administration (FDA) following an inspection of its formulations manufacturing facility in Kothur, Hyderabad.
The inspection was conducted between November 12 and November 20, 2026. The observations were issued in Form 483, which the US FDA uses to communicate concerns identified during inspections of manufacturing facilities.
Natco Pharma said it believes the observations are procedural in nature and is confident of addressing them within the stipulated timelines.
“The Company believes that the observations are procedural in nature and is confident of addressing these observations comprehensively within stipulated timelines,” it said in an exchange filing on November 21.
The inspection covered the company’s formulations manufacturing facility, which makes finished pharmaceutical products. The company did not provide details of the seven observations in its filing.
A Form 483 is issued when FDA investigators identify conditions that may violate regulatory requirements during an inspection. It is not the same as a warning letter or a final regulatory decision. Companies are generally expected to respond to the observations and explain the corrective steps they plan to take.
Headquartered in Hyderabad, Natco Pharma develops and manufactures generic and branded medicines, speciality pharmaceuticals and active pharmaceutical ingredients (APIs). It has manufacturing facilities approved by several regulatory authorities, including the US FDA, Brazil’s ANVISA, Health Canada and the World Health Organization.
